Kenny John P. 4

What Happened
Kenny John P., a director of NEOGENOMICS, reported the conversion/vesting of derivative awards on 2026-06-01 that resulted in the acquisition of 32,932 shares of common stock at $0.00 per share (total reported value $0). The filing also shows a simultaneous disposition of 5,893 derivative shares (reported at $0). Net, the transactions increased his share holdings by 27,039 shares (32,932 acquired minus 5,893 disposed). These transactions reflect awards/vesting and conversion of previously granted derivative instruments rather than an open-market purchase or sale.

Key Details

• Transaction date(s): 2026-06-01; Form 4 filed 2026-06-03 (timely within the two-business-day window).
• Reported transactions:
  • Exercise/conversion (code M): 5,893 shares acquired at $0.00; 5,893 shares disposed at $0.00 (derivative).
  • Grant/award (code A): 11,069 shares acquired at $0.00 (derivative).
  • Grant/award (code A): 15,970 shares acquired at $0.00 (derivative).
• Reported dollar values: all transactions reported at $0.00 per share (total reported value $0).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — release of restricted stock units (RSUs) previously reported on a Form 4; F2 — once vested the shares are not subject to expiration.
• Filing timeliness: filed 2026-06-03 for 2026-06-01 transactions (appears timely).

Context

• "Exercise/conversion" and "grant/award" here indicate conversion/vesting of derivative awards (likely RSUs or similar) into common stock rather than a cash purchase. The simultaneous disposition of 5,893 shares (reported at $0) is documented but the Form 4 does not state the reason; such disposals commonly represent share surrender for tax withholding or to cover exercise-related costs.
• These entries are routine for vested awards and do not, by themselves, indicate a buy or sell opinion by the insider.